# OnCo record breast-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/breast-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "breast-cancer-signalling" ;
  schema:name "Breast cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05224"@en, "Breast cancer"@en ;
  schema:description "KEGG's breast cancer map lays out the three clinical subtypes as signalling routes: oestrogen receptor driving cyclin D and CDK4/6 in hormone-receptor-positive disease, HER2 driving PI3K/AKT and MAPK in HER2-positive disease, and EGFR, Notch, Wnt and BRCA defects in triple-negative disease. Each route has its own drug class."@en ;
  schema:url <https://onco.cc/pathways/breast-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05224>, <https://doi.org/10.1038/s41572-019-0111-2> ;
  onco:related <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-harbeck-nat-rev-dis-primers/> .